Semaglutide has an elimination half-life of about one week, so it takes roughly 4 to 5 weeks of consistent daily dosing at any given dose just to reach steady levels in your blood. The standard titration adds roughly a month each at 1.5 mg, 4 mg and 9 mg before reaching the 25 mg maintenance dose around day 91.
Put together, meaningful appetite change and weight loss build gradually across the first three to four months. They do not appear in the first fortnight. Judging the medicine too early, before the maintenance dose has had time to work, is one of the most common reasons people conclude wrongly that it is not working.
Across the published trials, oral Wegovy's average result sits close to the standard weekly injection and above the first competing oral pill, though none of these were tested head-to-head against each other.
| Trial | Product | Duration | Mean weight loss |
|---|---|---|---|
| OASIS 4 | Oral Wegovy 25 mg | 64 weeks | 16.6% (13.6% including early stoppers) |
| STEP 1 | Wegovy 2.4 mg injection | 68 weeks | 14.9% |
| STEP UP | Wegovy 7.2 mg injection | ~68 weeks | 20.7% |
| ATTAIN-1 | Orforglipron, oral | 72 weeks | 11.2% |
| SURMOUNT-1 | Tirzepatide, injection | 72 weeks | up to 20.9% |
Different trials used different populations, durations and analysis methods, so these figures are not directly comparable to each other.
About one in three people on oral Wegovy 25 mg in OASIS 4 lost 20% or more of their body weight, against under 3% on placebo, alongside improvements in blood pressure and cholesterol. These are group averages from controlled trials. Your own result depends on your starting point, your consistency with the routine, and how well you tolerate the medicine, among other things.
Absorption of the tablet varies considerably from person to person, with published between-person variability in exposure of around 56%. There is currently no test to predict in advance who will absorb more or less.
There is, however, a reassuring pattern in the same data. Day-to-day variability within the same person is very high after a single dose, around 137%, but falls sharply with consistent daily dosing, to around 33% once dosing is established, because each day's dose adds to an existing reservoir rather than starting from zero.
In practice, this means consistency in how and when you take the tablet is one of the few things genuinely within your control that affects how well it works for you.
Most of what determines your result is either fixed, meaning how much you personally absorb, or slow, meaning the months it takes to reach maintenance. The parts you can actually influence are these.
- Get the routine right, every day. This matters more for the tablet than for almost any other oral medicine. See how to take oral Wegovy for the full detail on timing, water and other tablets.
- Do not judge it before the maintenance dose has had time to work. Give the full titration period plus several weeks at 25 mg before drawing conclusions.
- Keep the diet and activity side genuinely in place. The medicine is licensed as an adjunct to a reduced-calorie diet and increased physical activity, not a replacement for either. It makes those changes easier to sustain, not unnecessary.
- Stay hydrated and eat sensibly around side effects. Smaller portions and avoiding very rich or greasy food tend to ease nausea for most people. Persistent vomiting or an inability to keep fluids down needs medical attention, not just dietary adjustment.
- Raise a flat response with your prescriber, not with a bigger dose you decide on yourself. If you are several weeks into 25 mg with genuinely no effect, the first things worth checking honestly are technique and any interacting medicines. See oral Wegovy and other medicines.
Gastrointestinal effects are by far the most common: nausea, vomiting, diarrhoea, constipation and indigestion. In OASIS 4, around 74% of people on the 25 mg dose had a gastrointestinal adverse event, against 42% on placebo, mostly clustered around dose increases and generally settling with time as the body adjusts.
Overall treatment discontinuation for side effects was around 7%, only slightly above the 6% on placebo, which suggests most people who experience side effects find them manageable enough to continue.
Most people tolerate oral Wegovy without serious problems. Contact a doctor, or seek urgent care, for any of the following.
- Severe or persistent abdominal pain, especially spreading to the back, which can signal pancreatitis or a gallbladder problem
- Vomiting that will not stop, or signs of dehydration
- Symptoms of low blood sugar (shakiness, sweating, confusion) if you also take insulin or a sulfonylurea for diabetes
- Signs of a serious allergic reaction (rash, swelling of the face or throat, difficulty breathing). This needs emergency care: call 112
- Any possibility you might be pregnant
Oral Wegovy is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and should not be used in pregnancy or while trying to conceive. If you are planning pregnancy, semaglutide can remain in your system for around 5 to 7 weeks after stopping, so this needs discussing with your prescriber well in advance rather than left until later.
Most people regain a substantial share of the weight they lost within a year of stopping. The clearest evidence is from the injectable form of the same molecule: in the STEP 1 extension, people who stopped weekly semaglutide 2.4 mg regained around two-thirds of their lost weight within a year.
There is no reason to expect the tablet to behave very differently, given it is the same molecule. If you are considering reducing or stopping, that is a conversation to have with your prescriber rather than a decision to make alone, because a planned approach tends to produce a better outcome than simply stopping.
Oral Wegovy is still not available in Spain. It was authorised for the whole EU on 15 July 2026, but Spain separately needs its own product information and a pricing notification, followed by supply reaching Spanish pharmacies, before it can be dispensed.
Going by the injectable form of the same medicine, which took about 28 months from EU authorisation to reaching Spanish pharmacies, this process can take considerably longer than a few months. No date has been confirmed as of late August 2026. The injectable pen has been available in Spain by private prescription since May 2024, at full private cost, because it is not funded by the Spanish national health system for weight management. Check the AEMPS CIMA medicines database for the current authorised status of any product.
We provide continuation prescriptions for medicines you already take, for adults physically in Spain, reviewed by a Spanish-registered English-speaking doctor.
- Prescribing or supplying oral Wegovy, which is not available in Spain
- Assessing whether a weight-management medicine is working for you
- Managing side effects of a weight-management medicine
- Starting, adjusting or stopping any weight-management medicine
Starting a new weight-management medicine sits outside our continuation-only remit regardless. That decision belongs with a dedicated GLP-1 service such as Nivelta, our sister service, also from Doctor Abbs SL. If you already take a different regular medicine and it has run out while you are here, start a clinical review.